53 related articles for article (PubMed ID: 20938875)
1. Predictors of death and survival duration among a sample of persons living With HIV/AIDS.
Reilly T; Smith L; Woodruff SI; Clapp JD; Cade J
Soc Work Health Care; 2010; 49(9):783-98. PubMed ID: 20938875
[TBL] [Abstract][Full Text] [Related]
2. Race, sex, drug use, and progression of human immunodeficiency virus disease.
Chaisson RE; Keruly JC; Moore RD
N Engl J Med; 1995 Sep; 333(12):751-6. PubMed ID: 7643881
[TBL] [Abstract][Full Text] [Related]
3. Gender-specific differences in the natural history, clinical features, and socioeconomic status of HIV-infected patients: experience of a treatment centre in Vienna.
Armbruster C; Kriwanek S; Vorbach H
Wien Klin Wochenschr; 2000 Sep; 112(17):754-60. PubMed ID: 11042904
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda.
Bajunirwe F; Tisch DJ; King CH; Arts EJ; Debanne SM; Sethi AK
AIDS Care; 2009 Mar; 21(3):271-9. PubMed ID: 19280404
[TBL] [Abstract][Full Text] [Related]
5. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
6. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
8. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS).
Farinpour R; Miller EN; Satz P; Selnes OA; Cohen BA; Becker JT; Skolasky RL; Visscher BR
J Clin Exp Neuropsychol; 2003 Aug; 25(5):654-70. PubMed ID: 12815503
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy and declining AIDS mortality in New York City.
Messeri P; Lee G; Abramson DM; Aidala A; Chiasson MA; Jessop DJ
Med Care; 2003 Apr; 41(4):512-21. PubMed ID: 12665715
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
11. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
Lima VD; Hogg RS; Harrigan PR; Moore D; Yip B; Wood E; Montaner JS
AIDS; 2007 Mar; 21(6):685-92. PubMed ID: 17413689
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
13. Psychosocial predictors of reported HIV-preventive behaviour change among adults in Bulawayo, Zimbabwe.
Wilson D; Dubley I; Msimanga S; Lavelle L
Cent Afr J Med; 1991 Jul; 37(7):196-202. PubMed ID: 1811902
[TBL] [Abstract][Full Text] [Related]
14. The impact of integrating food supplementation, nutritional education and HAART (Highly Active Antiretroviral Therapy) on the nutritional status of patients living with HIV/AIDS in Mozambique: results from the DREAM Programme.
Scarcella P; Buonomo E; Zimba I; Doro Altan AM; Germano P; Palombi L; Marazzi MC
Ig Sanita Pubbl; 2011; 67(1):41-52. PubMed ID: 21468153
[TBL] [Abstract][Full Text] [Related]
15. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.
Onen NF; Overton ET; Presti R; Blair C; Powderly WG; Mondy K
HIV Med; 2009 Aug; 10(7):439-46. PubMed ID: 19459993
[TBL] [Abstract][Full Text] [Related]
16. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
17. Analysis of survival in HIV-infected subjects according to socio-economic resources in the HAART era.
Liotta G; Caleo GM; Mancinelli S
Ann Ig; 2008; 20(2):95-104. PubMed ID: 18590041
[TBL] [Abstract][Full Text] [Related]
18. Increased health care utilization and increased antiretroviral use in HIV-infected individuals with mental health disorders.
Mijch A; Burgess P; Judd F; Grech P; Komiti A; Hoy J; Lloyd JH; Gibbie T; Street A
HIV Med; 2006 May; 7(4):205-12. PubMed ID: 16630032
[TBL] [Abstract][Full Text] [Related]
19. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
20. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System?
Borrell C; Rodríguez-Sanz M; Pasarín MI; Brugal MT; García-de-Olalla P; Marí-Dell'Olmo M; Caylà J
Eur J Public Health; 2006 Dec; 16(6):601-8. PubMed ID: 16698886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
